Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| INV-017062 | Other Grant/Funding Number | Bill and Melinda Gates Foundation |
Not provided
Not provided
Not provided
Low number of events contributing to primary outcome
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bill and Melinda Gates Foundation | OTHER |
Not provided
Not provided
Not provided
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
This is a randomized, multi-center, placebo-equivalent (ascorbic acid + folic acid)-controlled, blinded platform trial. Eligible participants will be enrolled and randomized to Hydrocychloroquine (HCQ) + placebo (folic acid), HCQ + azithromycin, lopinavir-ritonavir (LPV/r) or placebo (ascorbic acid + folic acid). Initially, this study will enroll up to 495 eligible adults ( with high risk for Lower respiratory tract infection (LRTI) progression at baseline who are PCR-confirmed SARS-CoV-2 infection (165 per arm). An additional cohort of 135 eligible adults without risk factors for LRTI progression at baseline who are PCR-confirmed SARS-CoV-2 infection will be enrolled for the co-primary virologic outcome. During the 28 study days, participants will take the medication, complete surveys, collect mid nasal swab for viral quantification, and assess symptoms for progression to LRTI. Additional arms will be added should new potential agents be discovered or combination treatments be proposed. In addition, arms may be dropped prior to completion if deemed futile or if there is a safety signal.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ascorbic acid and Folic acid | Placebo Comparator | Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5) |
|
| Hydroxychloroquine and Folic Acid | Experimental | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5]) |
|
| Hydroxychloroquine and Azithromycin | Experimental | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5). |
|
| Lopinavir-ritonavir | Experimental | LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10) |
|
| Ascorbic acid |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ascorbic Acid | Drug | Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Persons With Lower Respiratory Tract Infection (LRTI), Defined as Resting Blood Oxygen Saturation (SpO2<93%) Level Sustained for 2 Readings 2 Hours Apart and Presence of Subjective Dyspnea or Cough | Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough | 28 days from enrolment |
| Number of Participants With Hospitalization or Mortality | Number of participants with hospitalization or mortality | Day 28 after enrolment |
| Time to Clearance of Nasal SARS-CoV-2 | Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabs | Day 1 through Day 14 after enrolment |
| Time to Resolution of COVID-19 Symptom Resolution in Days | COVID-19 symptoms are based on the following criteria:
| Day 1 through Day 14 after enrolment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Serious Adverse Events and Adverse Events Resulting in Treatment Discontinuation | Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuation | 28 days from enrolment |
| COVID-19-related Hospitalization Days |
Not provided
Inclusion Criteria:
Men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent
Willing and able to provide informed consent
Laboratory confirmed SARS-CoV-2 infection, with test results within past 72 hours
COVID-19 symptoms, based on the following criteria: At least TWO of the following symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR o At least ONE of the following symptoms: cough, shortness of breath or difficulty breathing (Lopinavir-Ritonavir Platform)
Access to device and internet for Telehealth visits
At increased risk of developing severe COVID-19 disease (at least one of the following)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christine Johnston, MD, MPH | University of Washington | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ruth M. Rothstein CORE Center - Cook County Health | Chicago | Illinois | 60612 | United States | ||
| Tulane University |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35604806 | Derived | Mayfield JJ, Chatterjee NA, Noseworthy PA, Poole JE, Ackerman MJ, Stewart J, Kissinger PJ, Dwyer J, Hosek S, Oyedele T, Paasche-Orlow MK, Paolino K, Friedman PA, Waters C, Moreno J, Leingang H, Heller KB, Morrison SA, Krows ML, Barnabas RV, Baeten J, Johnston C; COVID-19 Early Treatment Team; Sridhar AR. Implementation of a fully remote randomized clinical trial with cardiac monitoring. Commun Med (Lond). 2021 Dec 20;1:62. doi: 10.1038/s43856-021-00052-w. eCollection 2021. | |
| 34473343 |
Not provided
Not provided
De-identified data from the study will be made available in accordance with the funder's open access policy.
Within 3 months of publication of primary results.
De-identified data from the study will be made available in accordance with the funder's open access policy.
This was a remotely conducted study. Participants who completed the informed consent process but did not complete the enrollment process after receiving the study materials are "started" but are not considered to have "completed enrollment". This explains the discrepancy between "Started" and "Completed Enrollment"
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ascorbic Acid and Folic Acid | Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5) Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy Folic Acid: Eligible participants in a household will receive folic acid and an additional intervention drug |
| FG001 | Hydroxychloroquine and Folic Acid | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5]) Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Folic Acid: Eligible participants in a household will receive folic acid and an additional intervention drug |
| FG002 | Hydroxychloroquine and Azithromycin | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5). Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Azithromycin: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy |
| FG003 | Lopinavir-ritonavir | LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]: Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy |
| FG004 | Ascorbic Acid | Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy |
| Title | Milestones | Reasons Not Completed | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ascorbic Acid and Folic Acid | Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5) Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy Folic Acid: Eligible participants in a household will receive folic acid and an additional intervention drug |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Persons With Lower Respiratory Tract Infection (LRTI), Defined as Resting Blood Oxygen Saturation (SpO2<93%) Level Sustained for 2 Readings 2 Hours Apart and Presence of Subjective Dyspnea or Cough | Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough | This outcome was analyzed in the first arm of the platform trial (Ascorbic Acid/Folic Acid HCQ, HCQ/AZ) among the high risk cohort only. The mITT cohort included only those without LRTI at baseline. | Posted | Count of Participants | Participants | 28 days from enrolment |
|
28 days
Participant reported AE
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ascorbic Acid and Folic Acid | Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5) Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy Folic Acid: Eligible participants in a household will receive folic acid and an additional intervention drug |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pneumonia | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Event leading to treatment discontinuation | Gastrointestinal disorders | Non-systematic Assessment |
Early termination of HCQ and HCQ/AZ arms as well as lopinavir-ritonavir arms leading to small numbers of participants analyzed.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Christine Johnston | University of Washington | 206-520-4340 | cjohnsto@uw.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol: Hydroxychloroquine and Azithromycin arms | Apr 11, 2020 | Oct 2, 2020 | Prot_002.pdf |
| Prot | Yes | No | No | Study Protocol: Lopinavir-Ritonavir arm | Aug 17, 2020 | Oct 2, 2020 | Prot_003.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 24, 2022 | Jan 24, 2022 | SAP_007.pdf |
| ICF | No | No | Yes | Informed Consent Form: Hydroxychloroquine and Azithromycin arms | Apr 15, 2020 | Oct 2, 2020 | ICF_004.pdf |
| ICF | No | No | Yes | Informed Consent Form: Lopinavir-Ritonavir arm | Aug 17, 2020 | Oct 2, 2020 | ICF_005.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D001205 | Ascorbic Acid |
| D006886 | Hydroxychloroquine |
| D017963 | Azithromycin |
| D005492 | Folic Acid |
| D061466 | Lopinavir |
| D019438 | Ritonavir |
| C558899 | lopinavir-ritonavir drug combination |
| ID | Term |
|---|---|
| D013400 | Sugar Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo Comparator |
Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days |
|
|
| Hydroxychloroquine Sulfate | Drug | Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy |
|
|
| Azithromycin | Drug | Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy |
|
|
| Folic Acid | Drug | Eligible participants in a household will receive folic acid and an additional intervention drug |
|
|
| Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] | Drug | Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy |
|
|
Duration of hospitalization among persons who become hospitalized with COVID-19 disease |
| 28 days from enrolment |
| New Orleans |
| Louisiana |
| 70118 |
| United States |
| Boston University | Boston | Massachusetts | 02215 | United States |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | United States |
| University of Washington Coordinating Center | Seattle | Washington | 98104 | United States |
| UW Virology Research Clinic | Seattle | Washington | 98104 | United States |
| Derived |
| Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. |
| 33681731 | Derived | Johnston C, Brown ER, Stewart J, Karita HCS, Kissinger PJ, Dwyer J, Hosek S, Oyedele T, Paasche-Orlow MK, Paolino K, Heller KB, Leingang H, Haugen HS, Dong TQ, Bershteyn A, Sridhar AR, Poole J, Noseworthy PA, Ackerman MJ, Morrison S, Greninger AL, Huang ML, Jerome KR, Wener MH, Wald A, Schiffer JT, Celum C, Chu HY, Barnabas RV, Baeten JM; COVID-19 Early Treatment Study Team. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinicalMedicine. 2021 Mar;33:100773. doi: 10.1016/j.eclinm.2021.100773. Epub 2021 Feb 27. |
| BG001 | Hydroxychloroquine and Folic Acid | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5]) Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Folic Acid: Eligible participants in a household will receive folic acid and an additional intervention drug |
| BG002 | Hydroxychloroquine and Azithromycin | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5). Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Azithromycin: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy |
| BG003 | Lopinavir-ritonavir | LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]: Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy |
| BG004 | Ascorbic Acid | Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy |
| BG005 | Total | Total of all reporting groups |
| Participants |
|
| Sex/Gender, Customized | Sex, defined at birth | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| High Risk | The high risk cohort included participants at increased risk of severe COVID-19 disease based on the following factors (at least one of the following) (see protocol for additional information and definitions):
| Count of Participants | Participants |
|
| OG001 | Hydroxychloroquine and Folic Acid | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5]) Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Folic Acid: Eligible participants in a household will receive folic acid and an additional intervention drug |
| OG002 | Hydroxychloroquine and Azithromycin | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5). Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Azithromycin: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy |
| OG003 | Lopinavir-ritonavir | LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]: Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy |
| OG004 | Ascorbic Acid | Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy |
|
|
| Primary | Number of Participants With Hospitalization or Mortality | Number of participants with hospitalization or mortality | Posted | Count of Participants | Participants | Day 28 after enrolment |
|
|
|
| Primary | Time to Clearance of Nasal SARS-CoV-2 | Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabs | Included the mITT viral shedding cohort, which includes the mITT cohort participants who do not meet the definition for clearance of viral shedding at baseline (day 1 and 2 swabs negative). | Posted | Median | 95% Confidence Interval | Days | Day 1 through Day 14 after enrolment |
|
|
|
| Primary | Time to Resolution of COVID-19 Symptom Resolution in Days | COVID-19 symptoms are based on the following criteria:
| mITT Disease Resolution cohort includes participants who meet the COVID-19 disease criteria on day 1. The symptom resolution rate was the primary outcome of the lopinavir-ritonavir adaptive platform arms (lopinavir-ritonavir and ascorbic acid). | Posted | Median | 95% Confidence Interval | Days | Day 1 through Day 14 after enrolment |
|
|
|
| Secondary | Number of Participants With Serious Adverse Events and Adverse Events Resulting in Treatment Discontinuation | Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuation | All enrolled participants | Posted | Count of Participants | Participants | 28 days from enrolment |
|
|
|
| Secondary | COVID-19-related Hospitalization Days | Duration of hospitalization among persons who become hospitalized with COVID-19 disease | Posted | Number | Days | 28 days from enrolment |
|
|
|
| 0 |
| 83 |
| 4 |
| 83 |
| 2 |
| 83 |
| EG001 | Hydroxychloroquine and Folic Acid | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5]) Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Folic Acid: Eligible participants in a household will receive folic acid and an additional intervention drug | 0 | 71 | 2 | 71 | 4 | 71 |
| EG002 | Hydroxychloroquine and Azithromycin | HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5). Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy Azithromycin: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy | 0 | 77 | 3 | 77 | 5 | 77 |
| EG003 | Lopinavir-ritonavir | LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]: Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy | 0 | 29 | 0 | 29 | 9 | 29 |
| EG004 | Ascorbic Acid | Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy | 0 | 29 | 1 | 29 | 0 | 29 |
| Chest Pain | Cardiac disorders | Non-systematic Assessment |
|
| Pulmonary embolism | Blood and lymphatic system disorders | Non-systematic Assessment |
|
| hemorrhagic colitis | Gastrointestinal disorders | Non-systematic Assessment |
|
| pericarditis | Cardiac disorders | Non-systematic Assessment |
|
| QT Prolongation | Cardiac disorders | Non-systematic Assessment |
|
| Headache | Nervous system disorders | Non-systematic Assessment |
|
| Drug Reaction | Immune system disorders | Non-systematic Assessment | Reaction or Hives |
|
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006880 |
| Hydroxy Acids |
| D002241 | Carbohydrates |
| D002738 | Chloroquine |
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D011622 | Pterins |
| D011621 | Pteridines |
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D001393 | Azoles |